Hypocalcaemia Articles

Articles

  • A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.

    Denosumab is an emerging new treatment for osteoporosis in postmenopausal women and men with non-metastatic prostate cancer. It is largely used by specialists as an alternative treatment in patients with contraindications to traditional, more commonly used drugs such as bisphosphonates.

    Published August 5, 2015
  • Hypercalcaemia and hypocalcaemia: finding the balance.

    The balance between bone formation and resorption may be disrupted in patients with cancer, leading either to increased bone resorption, calcium release, and possibly hypercalcaemia, or to increased bone formation, sequestration of calcium, and possibly hypocalcaemia.

    Published January 20, 2017
  • Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

    This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab.

    Laboratory abnormalities and adverse events of hypocalcaemia in patients with metastatic bone disease were analysed using data from three identically designed phase 3 trials of subcutaneous denosumab 120mg (n=2841) versus intravenous zoledronic acid 4mg (n=2836).

    Published September 2, 2015